Latest Blog And Researches

Date

15-02-2024 10:49:57pm

Exploring the Link Between Diabetes and Sleep: Unveiling the Impact of Sleep on Blood Sugar Levels

By: By Dr Aqsa Zafar, Pharma Lord | Tags: SLEEP DIABETES CIRCADIAN RHYTHM INSULIN RESISTANCE

This insightful blog explores the intricate relationship between sleep and diabetes, emphasizing the impact of sleep on blood sugar levels. Covering topics such as circadian rhythm, insulin resistance, chronotypes, sleep disorders, hormonal dynamics, and practical tips, it provides a holistic understanding of the Diabetes-Sleep Connection. The article concludes by highlighting the crucial role of cultivating healthy sleep habits for effective diabetes management and overall well-being.

READ MORE

Date

2023-12-15 23:18:53

Hydrogel-Based Controlled Drug Delivery for Cancer Treatment: A Review

By: Pharma Lord | Tags: hydrogel, cancer, drug delivery systems, stimuli-responsive materials

As an emerging drug carrier, hydrogels have been widely used for tumor drug delivery. A hydrogel drug carrier can cause less severe side effects than systemic chemotherapy and can achieve sustained delivery of a drug at tumor sites. In addition, hydrogels have excellent biocompatibility and biodegradability and lower toxicity than nanoparticle carriers. Smart hydrogels can respond to stimuli in the environment (e.g., heat, pH, light, and ultrasound), enabling in situ gelation and controlled drug release, which greatly enhance the convenience and efficiency of drug delivery.

READ MORE

Date

2023-12-14 23:38:27

CURRENT LANDSCAPE FROM CLINICAL TRIALS AND FUTURE OF COMBINEDCHECKPOINTS BLOCKADE IMMUNOTHERAPY IN CANCERS

By: Pharma Lord | Tags: CANCER, IMMUNOTHERAPY,CLINICAL TRIALS

Immunotherapy is among cancer immunology's fastest and most furious treatment strategies. The therapeutic perspective of checkpoint inhibitors is represented through the Food and Drug Administration (FDA) approvals for their implementation in various malignancies. Efforts to improve results with immunotherapeutic agents have led to the design of advanced treatment strategies. Current preclinical evidence estimating immune checkpoint inhibitors in several cancer cell lines has recommended that combinatorial approaches may have better survival results than monotherapy. Experimental trials evaluating combined therapy with anti-PD-1/ PD-L1 plus anti-CTLA-4 checkpoint inhibitors have reported considerable leads in survival indices over single immunotherapy. The therapeutic prospective of combinatorial approaches is focused on nivolumab with ipilimumab for advanced melanoma patients. Combined checkpoint inhibition with anti-PD-1/PDL1 plus anti-CTLA-4 monoclonal antibodies is bein

READ MORE